Child and Young Adult (CAYA) Cancer Outcomes Review
Improving Cancer Outcomes for Children, Adolescents, and Young Adults: A Multicenter Retrospective Cohort Study on Treatment Failure and Toxicity in Low- and Middle-Income Countries
This project looks at past treatment results to see what affects outcomes for children and young adults (ages 0–21) with leukemia and other cancers treated at participating centers in low- and middle-income countries.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 18000 (estimated) |
| Ages | 0 Years to 21 Years |
| Sex | All |
| Sponsor | Resonance, Inc. Academic / other |
| Drugs / interventions | Chemotherapy, Immunotherapy, Radiation |
| Locations | 5 sites (Yerevan and 4 other locations) |
| Trial ID | NCT07246213 on ClinicalTrials.gov |
What this trial studies
This retrospective cohort review collects medical record data from participating centers in low- and middle-income countries to describe treatment patterns and outcomes for children and young adults (0–21) diagnosed with cancer in the past 15 years, with a focus on acute lymphoblastic leukemia and lymphoblastic lymphoma. Data will include diagnosis details, treatments (chemotherapy, surgery, radiation, immunotherapy), timing of care, comorbidities, and outcomes such as treatment failure and survival. The project aims to identify system- and patient-level factors linked to poor outcomes and to inform targeted, evidence-based interventions to reduce disparities. The registry is led by Resonance, Inc. with collaborators including Servier and site partners in Armenia, El Salvador, and Guatemala.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with any cancer between ages 0 and 21 within the 15 years before the site's activation who received substantial anti-cancer treatment at a participating center and whose medical records are available.
Not a fit: Patients treated outside participating centers, those without accessible medical records, individuals older than 21 at diagnosis, or diagnoses older than 15 years are unlikely to be included or to benefit directly.
Why it matters
Potential benefit: If successful, the findings could guide interventions and policies that reduce treatment failures and improve survival for children and young adults with cancer in LMICs.
How similar studies have performed: Retrospective registries in high-income countries have previously guided major improvements in pediatric leukemia outcomes, and smaller LMIC registry projects have shown beneficial local changes, but comprehensive multi-country CAYA outcome data in LMICs remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria:
Subjects must meet all the following criteria to be included in this registry:
1. Participants must be willing and able to provide informed consent prior to enrollment in the registry.
1. For minors or individuals unable to provide informed consent, assent must be obtained along with consent from a legal guardian.
2. Note: Exemption applies to this criterion when waiver of informed consent/assent is granted by Institutional Review Board(IRB)/Independent Ethics Committee(IEC)/Competent Authorities(CAs).
2. A confirmed diagnosis of any type of cancer within the 15 years prior to the site's activation date.
3. Age 0 to 21 years at the time of diagnosis.
4. Received substantial anti-cancer treatment at the participating center, including but not limited to:
1. Chemotherapy
2. Surgery
3. Radiation therapy
4. Immunotherapy
5. Medical records are available and accessible for review
Exclusion Criteria:
* Subjects meeting any of the following criteria will be excluded from this registry:
1. Patients who only visited the participating center for:
1. Consultation without subsequent primary anti-cancer treatment at the participating center
2. Pathology, radiology, or other diagnostic evaluations without treatment
Where this trial is running
Yerevan and 4 other locations
- Yeolyan Center for Cancer and Blood Disorders — Yerevan, Armenia (Recruiting)
- Fundación Ayúdame a Vivir — El Salvador, El Salvador, El Salvador (Not_yet_recruiting)
- Unidad Nacional de Oncología Pediátrica (UNOP) — Guatemala City, Guatemala (Recruiting)
- Hospital Mario Catarino Rivas — San Pedro Sula, Cortés Department, Honduras (Not_yet_recruiting)
- Hospital Escuela — Tegucigalpa, Distrito Central, Honduras (Not_yet_recruiting)
Study contacts
- Study coordinator: Gabriela Villanueva, MD.
- Email: gabriela.villanueva@resonancehealth.org
- Phone: +1-901-205-9518
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.